Tonix Pharmaceuticals (TNXP) Works On Potential Treatment Of Long COVID-19 Syndrome: Golden Opportunity To Make Big Bucks?

Since June 14, when Tonix’s stock was $1.38, it was on a constant decline. Today, the price is predicted to be at $1.04, resulting in a 25% loss. However, keep an eye on this company. Tonix plans to meet with the US Food and Drug Administration (FDA) in the third quarter of 2021 to discuss the design of a potential main Phase 2 study and an overall clinical development plan to qualify TNX-102 SL as prescribed treatment for Long COVID Syndrome.
The company confirmed plans to promote TNX-102 SL for a potential treatment for long-term COVID syndrome, officially identified as post-acute effects of COVID-19. Tonix plans to meet with the FDA in the third quarter of 2021 to discuss a possible Phase 2 study design as well as a clinical advancement plan for TNX-102 SL approval for long-term COVID treatment. So, TNXP stocks are worth a look in the coming months.

Related:  Sundial Growers (SNDL) Soars 50% This Week As Pot Sector Picks Up

Tonix recently announced its inclusion in the Russell 3000 and Russell 2000 indexes from June 28, 2021. Notably, these additions are part of Russell’s annual recovery. Tonix CEO Seth Lederman said they are honored to be added to the indexes, as a result of the company’s success and positive growth over the past year. He said the indices are being widely followed and will strive for wider awareness of Tonix once added.

Richard McEntire

Finance and Entertainment Reporter Richard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.

Want Hot Stocks?    Yes. I Love Them No thanks